JP2007536277A - 安定化されたヒアルロナン調製物及びその方法 - Google Patents
安定化されたヒアルロナン調製物及びその方法 Download PDFInfo
- Publication number
- JP2007536277A JP2007536277A JP2007511718A JP2007511718A JP2007536277A JP 2007536277 A JP2007536277 A JP 2007536277A JP 2007511718 A JP2007511718 A JP 2007511718A JP 2007511718 A JP2007511718 A JP 2007511718A JP 2007536277 A JP2007536277 A JP 2007536277A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronan
- composition
- polyglycol
- average molecular
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 83
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title claims abstract description 80
- 229940099552 hyaluronan Drugs 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims description 28
- 229920000151 polyglycol Polymers 0.000 claims abstract description 37
- 239000010695 polyglycol Substances 0.000 claims abstract description 37
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 22
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 2
- 238000005057 refrigeration Methods 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010060932 Postoperative adhesion Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004485 insufficient tear production Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- -1 pH regulators Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56940704P | 2004-05-07 | 2004-05-07 | |
| PCT/US2005/016271 WO2005110439A2 (en) | 2004-05-07 | 2005-05-09 | Stabilized hyaluronan preparations and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007536277A true JP2007536277A (ja) | 2007-12-13 |
| JP2007536277A5 JP2007536277A5 (https=) | 2008-06-26 |
Family
ID=35394663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511718A Pending JP2007536277A (ja) | 2004-05-07 | 2005-05-09 | 安定化されたヒアルロナン調製物及びその方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7544671B2 (https=) |
| EP (1) | EP1746884A4 (https=) |
| JP (1) | JP2007536277A (https=) |
| AU (1) | AU2005244059A1 (https=) |
| CA (1) | CA2565944C (https=) |
| MX (1) | MXPA06013056A (https=) |
| WO (1) | WO2005110439A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509528A (ja) * | 2012-03-09 | 2015-03-30 | ドン−ア エスティ カンパニー リミテッド | ピロキシカムまたはその薬学的に許容される塩とヒアルロン酸またはその薬学的に許容される塩とを含む安定な液状の医薬組成物およびその製造方法 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070104798A1 (en) | 1999-10-04 | 2007-05-10 | S.K. Pharmaceuticals, Inc. | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |
| FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
| US20070031468A1 (en) * | 2005-08-04 | 2007-02-08 | Endomedix, Inc. | Modified chitosan for vascular embolization |
| US20070031467A1 (en) * | 2005-08-04 | 2007-02-08 | Abrahams John M | Composition and method for vascular embolization |
| TW200733993A (en) * | 2005-11-03 | 2007-09-16 | Reseal Internat Ltd Partnership | Continuously sealing one way valve assembly and fluid delivery system and formulations for use therein |
| US20080075657A1 (en) * | 2006-04-18 | 2008-03-27 | Abrahams John M | Biopolymer system for tissue sealing |
| US20070243130A1 (en) * | 2006-04-18 | 2007-10-18 | Weiliam Chen | Biopolymer system for tissue sealing |
| US7854923B2 (en) * | 2006-04-18 | 2010-12-21 | Endomedix, Inc. | Biopolymer system for tissue sealing |
| US20080124395A1 (en) * | 2006-06-22 | 2008-05-29 | Weiliam Chen | Formulations and devices for treatment or prevention of neural ischemic damage |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| DE102006049580A1 (de) * | 2006-10-20 | 2008-04-24 | Rochel, Michael, Dr. med. | Topische Zusammensetzung zur Behandlung von Ekzemen |
| WO2009006130A2 (en) * | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
| WO2010030725A1 (en) * | 2008-09-15 | 2010-03-18 | Bausch & Lomb Incorporated | Compositions comprising polymers having amino sugar units and methods of making and using same |
| WO2010125069A1 (en) * | 2009-04-28 | 2010-11-04 | Pharmasurgics In Sweden Ab | Hyaluronic acid for preventing post surgical adhesions |
| IT1394223B1 (it) | 2009-05-15 | 2012-06-01 | Thea Sas Lab | Kit per la valutazione e la selezione personalizzata di lacrime artificiali |
| US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
| US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| DE102011077393A1 (de) * | 2011-06-10 | 2012-12-13 | Johannes Reinmüller | Antiinfektives Mittel |
| US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| EP4137139A1 (en) | 2013-07-10 | 2023-02-22 | Matrix Biology Institute | Compositions of hyaluronan with high elasticity and uses thereof |
| US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
| PL3352766T3 (pl) | 2015-09-24 | 2021-08-02 | Matrix Biology Institute | Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia |
| EP3231417B1 (de) * | 2016-04-15 | 2018-12-05 | Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH | Lagerungsstabile, ophthalmische zusammensetzung |
| DE102018124022A1 (de) | 2018-09-28 | 2020-04-02 | Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen | Hyaluronsäurestabilisator |
| US10517988B1 (en) | 2018-11-19 | 2019-12-31 | Endomedix, Inc. | Methods and compositions for achieving hemostasis and stable blood clot formation |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2160097A (en) * | 1984-06-11 | 1985-12-18 | Biomatrix Inc | Hyaluronate/poly (ethylene oxide) compositions |
| JPH05170641A (ja) * | 1991-12-25 | 1993-07-09 | Shiseido Co Ltd | 化粧料 |
| JPH09227385A (ja) * | 1996-02-29 | 1997-09-02 | Ofutekusu:Kk | 眼手術用補助剤 |
| JPH1072376A (ja) * | 1996-09-02 | 1998-03-17 | Ofutekusu:Kk | ヒアルロン酸含有点眼水溶液 |
| JPH10290830A (ja) * | 1997-04-18 | 1998-11-04 | Ofutekusu:Kk | 眼手術用補助剤 |
| JP2001019611A (ja) * | 1999-07-08 | 2001-01-23 | Pola Chem Ind Inc | 皮膚外用組成物 |
| JP2002193815A (ja) * | 2000-12-25 | 2002-07-10 | Ophtecs Corp | 眼手術用角膜乾燥防止点眼剤 |
| US20020127196A1 (en) * | 2000-11-28 | 2002-09-12 | Focal, Inc. | Polyalkylene glycol viscosity-enhancing polymeric formulations |
| JP2002370966A (ja) * | 2001-05-29 | 2002-12-24 | L'oreal Sa | 皮膚加齢の徴候を処置するための組成物 |
| WO2003061626A1 (en) * | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| JP2003530136A (ja) * | 1999-04-02 | 2003-10-14 | フジオメッド インコーポレイテッド | ポリ酸及びポリエーテルの組成物及び接着の低減におけるその使用方法 |
| JP2003342197A (ja) * | 2002-03-18 | 2003-12-03 | Wakamoto Pharmaceut Co Ltd | ヒアルロン酸含有熱ゲル化製剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6479103A (en) * | 1987-06-09 | 1989-03-24 | Lion Corp | External preparation |
| US5141741A (en) * | 1988-12-09 | 1992-08-25 | Lion Corporation | Anti-sunburn skin-care preparation |
| KR100514963B1 (ko) * | 1997-07-11 | 2005-09-15 | 도레이 가부시끼가이샤 | 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물 |
| US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
| US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
-
2005
- 2005-05-09 US US11/126,075 patent/US7544671B2/en not_active Expired - Lifetime
- 2005-05-09 EP EP05747840A patent/EP1746884A4/en not_active Ceased
- 2005-05-09 WO PCT/US2005/016271 patent/WO2005110439A2/en not_active Ceased
- 2005-05-09 MX MXPA06013056A patent/MXPA06013056A/es unknown
- 2005-05-09 JP JP2007511718A patent/JP2007536277A/ja active Pending
- 2005-05-09 CA CA2565944A patent/CA2565944C/en not_active Expired - Lifetime
- 2005-05-09 AU AU2005244059A patent/AU2005244059A1/en not_active Abandoned
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2160097A (en) * | 1984-06-11 | 1985-12-18 | Biomatrix Inc | Hyaluronate/poly (ethylene oxide) compositions |
| JPH05170641A (ja) * | 1991-12-25 | 1993-07-09 | Shiseido Co Ltd | 化粧料 |
| JPH09227385A (ja) * | 1996-02-29 | 1997-09-02 | Ofutekusu:Kk | 眼手術用補助剤 |
| JPH1072376A (ja) * | 1996-09-02 | 1998-03-17 | Ofutekusu:Kk | ヒアルロン酸含有点眼水溶液 |
| JPH10290830A (ja) * | 1997-04-18 | 1998-11-04 | Ofutekusu:Kk | 眼手術用補助剤 |
| JP2003530136A (ja) * | 1999-04-02 | 2003-10-14 | フジオメッド インコーポレイテッド | ポリ酸及びポリエーテルの組成物及び接着の低減におけるその使用方法 |
| JP2001019611A (ja) * | 1999-07-08 | 2001-01-23 | Pola Chem Ind Inc | 皮膚外用組成物 |
| US20020127196A1 (en) * | 2000-11-28 | 2002-09-12 | Focal, Inc. | Polyalkylene glycol viscosity-enhancing polymeric formulations |
| JP2002193815A (ja) * | 2000-12-25 | 2002-07-10 | Ophtecs Corp | 眼手術用角膜乾燥防止点眼剤 |
| JP2002370966A (ja) * | 2001-05-29 | 2002-12-24 | L'oreal Sa | 皮膚加齢の徴候を処置するための組成物 |
| WO2003061626A1 (en) * | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| JP2003342197A (ja) * | 2002-03-18 | 2003-12-03 | Wakamoto Pharmaceut Co Ltd | ヒアルロン酸含有熱ゲル化製剤 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509528A (ja) * | 2012-03-09 | 2015-03-30 | ドン−ア エスティ カンパニー リミテッド | ピロキシカムまたはその薬学的に許容される塩とヒアルロン酸またはその薬学的に許容される塩とを含む安定な液状の医薬組成物およびその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1746884A2 (en) | 2007-01-31 |
| US7544671B2 (en) | 2009-06-09 |
| EP1746884A4 (en) | 2010-01-13 |
| CA2565944A1 (en) | 2005-11-24 |
| MXPA06013056A (es) | 2007-04-17 |
| AU2005244059A1 (en) | 2005-11-24 |
| CA2565944C (en) | 2011-07-19 |
| WO2005110439A2 (en) | 2005-11-24 |
| US20060029571A1 (en) | 2006-02-09 |
| WO2005110439A3 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7544671B2 (en) | Stabilized hyaluronan preparations and related methods | |
| US20210128604A1 (en) | Stabilized Glycosaminoglycan Preparations and Related Methods | |
| US20190000740A1 (en) | Hyaluronic acid composition | |
| JP2003528906A (ja) | ドライアイを処置するための方法 | |
| CN105705137A (zh) | 获得基于含有以粉末形式添加的利多卡因和碱剂的透明质酸且热灭菌的可注射水凝胶的方法 | |
| KR20150023468A (ko) | 하나 이상의 히알루론산 및 하나 이상의 수크로스 옥타설페이트 수용성 염을 포함하는 수성 매질 중 조성물 | |
| US20060293277A1 (en) | Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making for making them | |
| US20100022472A1 (en) | Liquid, eye-instillable preparations comprising sodium hyaluronate | |
| CN109157539A (zh) | 具有改善的干燥保护和保留的眼用组合物 | |
| EP2349251B1 (en) | Topical formulations with a tertiary amine oxide | |
| HUE025500T2 (en) | Viscoelastic gels for ophthalmic surgery | |
| JP7093372B2 (ja) | 新規な粘弾性溶液及びそのリウマチ学における使用 | |
| JPH1143446A (ja) | 水性製剤の増粘剤 | |
| DE10053866A1 (de) | Bioverträgliche Flüssigformulierungen für human- und veterinärmedizinische Anwendungen als Gleitmittel | |
| KR102329495B1 (ko) | 소듐 2-메르캅토에탄 설포네이트를 삼투압 조절제로서 함유하는 생체투여 또는 미용성형용 생분해성 고분자 조성물 | |
| EP3890699B1 (en) | Hypertonic ophthalmic ointment | |
| TW200829260A (en) | Method of stimulating the production of mucin in the eye of a patient | |
| EP4426265A1 (en) | Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject | |
| CN118526516A (zh) | 一种高渗透性的隐形眼镜护理液及其制备方法 | |
| CN121695172A (zh) | 眼用组合物及其在眼睛疾病治疗中的应用 | |
| CN107249554B (zh) | 含有2-巯基乙磺酸钠的透明质酸的分解抑制剂及包含其的组合物 | |
| HK1248100A1 (zh) | 眼用原位凝胶处方 | |
| EA039966B1 (ru) | Применение жидкой фармацевтической композиции, содержащей хондроитин сульфат и гиалуроновую кислоту |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080508 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110815 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120702 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130204 |